Thymic Carcinoma Clinical Trial
Official title:
A Phase II, Non-comparative, Open Label, Multi-center Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma
This study aims to investigate the clinical activity of sunitinib in patients with advanced thymic carcinoma who have failed chemotherapy.
Sunitinib (Sutent®; Pfizer, New York, NY, USA) is a multitargeted tyrosine-kinase inhibitor
(TKI) with activity against the stem cell-factor receptor (KIT) and platelet-derived
growth-factor receptor (PDGFR), vascular endothelial growth-factor receptor (VEGFR), glial
cell line-derived neurotrophic factor receptor (rearranged during transfection [RET]),
colony-stimulating factor-1 receptor (CSF1R), and Fms-like tyrosine kinase-3 receptor (FLT3).
Sunitinib is a potent inhibitor of mutant KIT with additional inhibitory effects on VEGF
receptors that potentially might make it more effective than imatinib against TCs. In the
current version of NCCN guideline, sunitinib is suggested as one of the potential targeted
therapeutics for advanced TCs.
We planned this study to investigate the clinical efficacy and tolerability of sunitinib in
patients with advanced or recurrent TCs in Korean population. In addition, we will collect
tumor samples and blood samples from patients for the further exploration of predictive
biomarkers.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06019468 -
Neoadjuvant Treatment For Locally Advanced Thymic Cancer
|
Phase 2 | |
| Terminated |
NCT00818090 -
Paclitaxel and Cisplatin for Thymic Neoplasm
|
Phase 2 | |
| Recruiting |
NCT03921671 -
Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)
|
Phase 2 | |
| Recruiting |
NCT06248515 -
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT02364076 -
Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
|
Phase 2 | |
| Terminated |
NCT01100944 -
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03449173 -
Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)
|
Phase 2 | |
| Recruiting |
NCT03556228 -
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
|
Phase 1 | |
| Completed |
NCT01364727 -
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
|
Phase 2 | |
| Suspended |
NCT03463460 -
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
|
Phase 2 | |
| Completed |
NCT00010257 -
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
|
Phase 2 | |
| Completed |
NCT04430842 -
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
|
Phase 1 | |
| Active, not recruiting |
NCT03583086 -
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03517488 -
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00198133 -
Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma
|
Phase 2 | |
| Recruiting |
NCT03170804 -
Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer
|
N/A | |
| Recruiting |
NCT05667948 -
Molecular Analysis and Treatment Options of Thymic Malignancies
|
||
| Terminated |
NCT01011439 -
Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
|
Phase 2 | |
| Terminated |
NCT01143545 -
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
|
Phase 1 | |
| Completed |
NCT02307500 -
Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
|
Phase 2 |